OBJECTIVES: To assess the impact of an employer-sponsored, pharmacist-provided MTM program on clinical outcomes in patients with diabetes and hypertension over a 24 month period. METHODS: A prospective, intent-to-treat, pre-post longitudinal study.  Patients were Lucas County employees and dependents with diabetes, hypertension, or a combination.  The MTM services were provided by independent pharmacists in Northwest Ohio at seven sites.  ADA and JNC-VII guidelines were used to design interventions and set patient goals. Data was analyzed using SPSS v17.0. Friedman test was used to compare readings at baseline, 12, and 24 months. RESULTS: To date 623 patients have enrolled in the MTM program, 41 with diabetes only, 224 with diabetes and one or more comorbidities, 85 with hypertension only, and 101 with hypertension with comorbidities.  A total of 190 patients with A1C values and 412 patients with blood pressure values were analyzed.  Mean A1C values increased from 7.14 ± 1.53 to 7.28 ± 1.52 for all patients. For uncontrolled patients, A1C decreased from 8.40 ± 1.57 to 8.03 ± 1.63. Diabetes patients decreased systolic blood pressure (SBP) from 133.59 ± 19.57 to 129.65 ± 16.04 and diastolic blood pressure (DBP) from 81.95 ± 10.38 to 79.49 ± 8.72. Uncontrolled patients decreased SBP from 147.65 ± 16.62 to 134.02 ± 14.99 and DBP decreased from 87.65 ± 6.66 to 82.31 ± 8.31. Hypertensive patients decreased SBP from 134.42 ± 17.28 to 129.86 ± 14.13 and DBP from 84.76 ± 10.97 to 81.76 ± 10.10. Uncontrolled hypertensive patients decreased SBP from 151.89 ± 11.10 to 134.95 ± 12.56 and DBP from 98.27 ± 6.24 to 85.71 ± 11.86. CONCLUSIONS: The pharmacists’ efforts have been shown to help decrease mean A1C and BP in patients. The improvements in these values help to decrease the risk for related complications and additional employer costs.